Home-Based Diuretic Therapy Feasible for Heart Failure Edema

A new study published in the Journal of the American College of Cardiology (JACC) has demonstrated the feasibility of at-home subcutaneous diuretic therapy for treating edema associated with heart failure. The SUBCUT HF II trial, involving SQ Innovation's product Lasix® ONYU, found that patients could self-administer the treatment, resulting in an average reduction of approximately four inpatient days per episode.

The multicenter, randomized controlled trial compared self-administered subcutaneous furosemide via a wearable pump to conventional intravenous treatment in a hospital setting. The study enrolled 172 patients with heart failure across 20 hospitals in the U.K. Results indicated that the at-home therapy achieved similar treatment outcomes to inpatient care, meeting its primary endpoint of reducing hospital stays.

Patients in the trial self-administered approximately 900 mg of furosemide over the course of their treatment, a dosage comparable to what might be given during a hospital admission. This finding supports previous evidence suggesting that subcutaneous administration can yield a similar diuretic effect to intravenous methods.

Lasix® ONYU, approved by the U.S. Food and Drug Administration (FDA) in October 2025, is designed for patients with chronic heart failure experiencing edema. The device slowly administers 80 mg of furosemide over five hours, mimicking IV administration's effectiveness while enabling home use. The trial's findings suggest a potential shift towards more patient-centered care, reducing healthcare system burdens by facilitating effective treatment outside the hospital.